These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 16914202)
1. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202 [TBL] [Abstract][Full Text] [Related]
2. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453 [TBL] [Abstract][Full Text] [Related]
3. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019 [TBL] [Abstract][Full Text] [Related]
4. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]. Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174 [TBL] [Abstract][Full Text] [Related]
6. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia. Nakata Y Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600 [TBL] [Abstract][Full Text] [Related]
7. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857 [TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648 [TBL] [Abstract][Full Text] [Related]
9. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192 [TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168 [TBL] [Abstract][Full Text] [Related]
11. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome. Chen ZX; Kaeda J; Saunders S; Goldman JM Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366 [TBL] [Abstract][Full Text] [Related]
12. Significance of FHIT expression in chronic myelogenous leukemia. Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340 [TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864 [TBL] [Abstract][Full Text] [Related]
14. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Proto-Siqueira R; Figueiredo-Pontes LL; Panepucci RA; Garcia AB; Rizzatti EG; Nascimento FM; Ishikawa HC; Larson RE; Falcão RP; Simpson AJ; Gout I; Filonenko V; Rego EM; Zago MA Leuk Res; 2006 Nov; 30(11):1333-9. PubMed ID: 16620968 [TBL] [Abstract][Full Text] [Related]
15. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients. Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770 [TBL] [Abstract][Full Text] [Related]
16. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients. Klobusická M; Kusenda J; Babusíková O Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061 [TBL] [Abstract][Full Text] [Related]